北京普祺医药

Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharma) is a clinical-stage biopharmaceutical company headquartered in Beijing, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company primarily focuses on immune-mediated inflammatory diseases, with a particular emphasis on dermatology and autoimmune disorders. Its core research centers on the development of highly selective Janus kinase (JAK) inhibitors, including its lead candidate PG-011, which is being investigated in various formulations for conditions such as atopic dermatitis and alopecia areata. Puqi Pharma leverages its internal R&D capabilities to advance a pipeline of candidates aimed at addressing significant unmet medical needs in the global immunology market.